Fulgent Genetics (FLGT) Liabilities and Shareholders Equity (2015 - 2026)

Fulgent Genetics has reported Liabilities and Shareholders Equity for 12 years, with the latest figure at $1.1 billion in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 9.22% year-over-year to $1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.7 billion (down 3.82% YoY) and the FY2025 annual result came in at $1.2 billion, down 0.53% from the prior year.
• Liabilities and Shareholders Equity eased to $1.1 billion in Q2 2026 per FLGT's latest filing, from $1.2 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.5 billion in Q1 2022 and troughed at $1.1 billion in Q2 2026.
• A 5-year average of $1.3 billion and a median of $1.2 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity surged 46.69% in 2022, then dropped 10.87% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.4 billion in 2022, then decreased by 10.87% to $1.2 billion in 2023, then declined by 1.24% to $1.2 billion in 2024, then slipped by 0.53% to $1.2 billion in 2025, then fell by 10.24% to $1.1 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.1 billion, $1.2 billion, and $1.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.